Home/Hedge Fund Intelligence/MoonLake Immunotherapeutics
Nasdaq: MLTXStockForm 13F30 Jun 2026

Hedge funds that hold MoonLake Immunotherapeutics Class A Ord Nasdaq: MLTX

Class A Ord · CUSIP 61559X104 · who reports it, how much, and how much it matters to them

39 of the 720 hedge fund managers we track reported shares of MoonLake Immunotherapeutics (Nasdaq: MLTX) on Form 13F for 30 June 2026. Between them they reported USD 596m. The largest position belongs to Deep Track Capital, at USD 136m. The manager with the most riding on it is Lion Point Capital, where it is 6.3% of the reported book.

Managers reporting it39of 720 we track
Value they reportUSD 596mshares only, 30 Jun 2026
Funds they run420with a file on PPLI.com
Largest positionUSD 136mDeep Track Capital
Typical weight0.0%median share of a manager's book
Heaviest weight6.3%Lion Point Capital

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

39 managers, USD 596m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports MoonLake Immunotherapeutics, largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Deep Track Capital1 fund on PPLI.comUSD 136m2.0%
2D. E. Shaw & Co.15 funds on PPLI.comUSD 66m0.0%
3Cormorant Asset Management1 fund on PPLI.comUSD 62m3.2%
4Logos Global Management1 fund on PPLI.comUSD 52m2.2%
5Weiss Asset Management5 funds on PPLI.comUSD 50m0.5%
6Citadel Advisors32 funds on PPLI.comUSD 38m0.0%
7Two Sigma Investments35 funds on PPLI.comUSD 33m0.0%
8POINT72 Asset Management17 funds on PPLI.comUSD 23m0.0%
9Balyasny Asset Management25 funds on PPLI.comUSD 18m0.0%
10Great Point Partners2 funds on PPLI.comUSD 17m3.1%
11Renaissance Technologies13 funds on PPLI.comUSD 13m0.0%
12Millennium Management6 funds on PPLI.comUSD 12m0.0%
13Marshall Wace LLP84 funds on PPLI.comUSD 11m0.0%
14Capricorn Fund Managers8 funds on PPLI.comUSD 7.3m0.6%
15Boxer Capital Management1 fund on PPLI.comUSD 5.4m0.4%
16Burkehill Global Management5 funds on PPLI.comUSD 4.9m0.2%
17Holocene Advisors2 funds on PPLI.comUSD 4.9m0.0%
18Walleye Capital8 funds on PPLI.comUSD 4.8m0.0%
19J. Goldman & Co.1 fund on PPLI.comUSD 4.2m0.1%
20Acuta Capital Partners2 funds on PPLI.comUSD 4.2m2.9%
21Verition Fund Management3 funds on PPLI.comUSD 4m0.0%
22HighVista Strategies27 funds on PPLI.comUSD 3.7m0.8%
23Voleon Capital Management13 funds on PPLI.comUSD 3.4m0.1%
24Exome Asset Management2 funds on PPLI.comUSD 3.2m2.0%
25Engineers Gate Manager1 fund on PPLI.comUSD 2.2m0.0%
26Polymer Capital Management (HK)1 fund on PPLI.comUSD 2m0.1%
27Jain Global1 fund on PPLI.comUSD 1.9m0.0%
28Squarepoint Ops7 funds on PPLI.comUSD 1.7m0.0%
29Lion Point Capital1 fund on PPLI.comUSD 1.3m6.3%
30Capital Fund Management S.A.12 funds on PPLI.comUSD 1.3m0.0%
31Tudor Investment Corporation10 funds on PPLI.comUSD 1.1m0.0%
32Exoduspoint Capital Management7 funds on PPLI.comUSD 908,0000.0%
33Campbell & Company Investment Adviser8 funds on PPLI.comUSD 578,0000.0%
34Aquatic Capital Management3 funds on PPLI.comUSD 548,0000.0%
35Schonfeld Strategic Advisors30 funds on PPLI.comUSD 537,0000.0%
36Prelude Capital Management9 funds on PPLI.comUSD 506,0000.0%
37Graham Capital Management18 funds on PPLI.comUSD 419,0000.0%
38Rock Springs Capital Management2 funds on PPLI.comUSD 208,0000.0%
39The Quarry1 fund on PPLI.comUSD 2,3360.0%
Next: where it matters most
Where it matters most

For Lion Point Capital it is 6.3% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Lion Point CapitalUSD 1.3m6.3%
2Cormorant Asset ManagementUSD 62m3.2%
3Great Point PartnersUSD 17m3.1%
4Acuta Capital PartnersUSD 4.2m2.9%
5Logos Global ManagementUSD 52m2.2%
6Exome Asset ManagementUSD 3.2m2.0%
7Deep Track CapitalUSD 136m2.0%
8HighVista StrategiesUSD 3.7m0.8%
9Capricorn Fund ManagersUSD 7.3m0.6%
10Weiss Asset ManagementUSD 50m0.5%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds MoonLake Immunotherapeutics

What is the ticker symbol of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics trades under the symbol MLTX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 61559X104.

Which hedge funds own MoonLake Immunotherapeutics (Nasdaq: MLTX)?

39 of the 720 hedge fund managers PPLI.com tracks reported MoonLake Immunotherapeutics shares on Form 13F for 30 June 2026. The largest reported positions were held by Deep Track Capital (USD 136m), D. E. Shaw & Co. (USD 66m), Cormorant Asset Management (USD 62m), Logos Global Management (USD 52m) and Weiss Asset Management (USD 50m).

How many hedge funds hold MoonLake Immunotherapeutics?

39 managers in our coverage reported it, and between them they run 420 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on MoonLake Immunotherapeutics?

Lion Point Capital, where the position was 6.3% of the reported 13F book at 30 June 2026.

Does this show who is short MoonLake Immunotherapeutics?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with MoonLake Immunotherapeutics or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.